LipotropiX
Natural health product licensed in Canada
- Licence holder
- Xymogen
- NPN or DIN-HM
- 80069501
- Status
- Active licence
- Licence date
- 17 May 2016
- Revision date
- 20 October 2016
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Choline Source : Dihydrogénocitrate de choline | 34.3 milligramme | Not calculated |
| Acide 2-aminoéthanesulfonique Source : Taurine | 50 milligramme | Not calculated |
| Taraxacum officinale Source : Racine Extraction ratio : 4:1 Dry plant equivalent : 150 milligramme | 37.5 milligramme | Not calculated |
| Chelidonium majus Source : Plante entière Extraction ratio : 10:1 Dry plant equivalent : 250 milligramme | 25 milligramme | Not calculated |
| Commiphora wightii Source : Gomme Extraction ratio : 12:1 Dry plant equivalent : 2,250 milligramme | 187.5 milligramme | Not calculated |
| Niacine Source : Hexanicotinate d'inositol | 187.5 milligramme | Not calculated |
| L-Méthionine | 100 milligramme | Not calculated |
Non-medicinal ingredients
NA, Silicate de calcium, Hypromellose, Stéarate de magnésium, Acide stéarique, Silice
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Helps the body to metabolize fats. Helps to support liver function.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner prior to use if you have liver or gall bladder diseases, and/or intestinal obstruction or a thyroid disorder, if you are taking beta-blockers (e.g. propranolol) or the calcium channel blockers, or if you have coagulation disorders and/or are at risk for bleeding or are taking anticoagulant or antiplatelet medication.
- Effets indésirables connus
May cause liver disorder in some people. People sensitive to nicotinic acid may experience flushing of the skin that is generally mild and transient. Discontinue use if gastrointestinal discomfort, headache and/or skin rash appear. Consult a healthcare practitioner immediately if you develop any of the following symptoms: nausea, vomiting, loss of appetite combined with itching, yellowing of the skin or eyes, dark urine.
Source
Official Health Canada record, licence 80069501
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2016. Photograph the packaging to check whether it has changed. Photograph the packaging